 Q BioMed Inc said it has received a Notice of Allowance for the patent of its Uttroside B asset in South Korea, adding to the patents already secured in Canada and Japan for the liver cancer chemotherapy candidate. The company said recent results from pre-clinical pharmacokinetic testing on Uttroside B have also been very encouraging and the data supports advancing the program. 